|Summary sheet: 4-HO-DiPT|
|Common names||4-HO-DiPT, Iprocin|
|Routes of Administration|
4-Hydroxy-N,N-diisopropyltryptamine (also known as 4-HO-DiPT and Iprocin) is a lesser-known psychedelic substance of the tryptamine class that produces psilocin-like psychedelic effects when administered. It is the 4-hydroxy analog of DiPT and is structurally related to tryptamines like 4-HO-DMT (Psilocin), 4-HO-MiPT (Miprocin), and 4-HO-DET (Ethocin).
Following the publication of its synthesis by David B. Repke in 1977, its effects in humans were investigated by Alexander Shulgin. It is characterized in his 1997 book TiHKAL ("Tryptamines I Have Known and Loved") and is noted for being unique among psychedelics in terms of its speed (apparent 15 minutes after ingestion), intensity (20 milligrams can produce a transcendent peak experience), brevity (2-3 hours), and dose sensitivity. Additionally, idiosyncratic physical effects like muscle tremors and bodily malaise were noted.
Today, 4-HO-DiPT is used for both recreational and entheogenic purposes. It is relatively uncommon and occasionally distributed on the online research chemical market. Very little is known about the pharmacological properties, metabolism, and toxicity in humans, and it has a limited history of human use. It is highly advised to use harm reduction practices if using this substance.
4-HO-DiPT, or 4-Hydroxy-N,N-diisopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine chemical class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-HO-DiPT is substituted at R4 of its indole heterocycle with a hydroxyl functional group OH−. It also contains two isopropyl groups bound to the terminal amine RN of its tryptamine backbone.
Like most psychedelic tryptamines, 4-HO-DiPT is thought to act principally as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 4-HO-DiPT's binding efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 4-HO-DiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-DiPT is a research chemical with very little history of human usage.
Anecdotal reports from those who have tried 4-HO-DiPT suggests that there are no negative health effects attributed to simply trying it by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
4-HO-DiPT is not habit-forming, and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.
Tolerance to the effects of 4-HO-DiPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-HO-DiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-HO-DiPT all psychedelics will have a reduced effect.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous or even life-threatening when combined with certain other substances. The following lists some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 4-HO-DiPT. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
- Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
Due to its relative obscurity, the possession and sale of 4-HO-DiPT is unscheduled in most countries.
- Germany: 4-HO-DiPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 4-HO-DiPT are punishable as an incitement to place it on the market.
- Sweden: 4-HO-DiPT is classified as a "health hazard" under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated to the "Act on the Prohibition of Certain Goods Dangerous to Health") as of March 1, 2005 in their regulation SFS 2005:26, making it illegal to sell or possess.
- Switzerland: 4-HO-DiPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.
- United Kingdom: 4-HO-DiPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: 4-HO-DiPT is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT), a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Florida: 4-HO-DiPT is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess.
- Shulgin, Alexander; Shulgin, Ann (1997). "#17. 4-HO-DIPT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
- Repke, D. B.; Ferguson, W. J.; Bates, D. K. (1977). "Psilocin analogs. 1. Synthesis of 3‐[2‐(dialkylamino)ethyl] ‐and 3‐[2‐(cycloalkylamino)ethyl] indol‐4‐ols". Journal of Heterocyclic Chemistry. 14 (1): 71–74. doi:10.1002/jhet.5570140113. ISSN 0022-152X. OCLC 1783072.
- Alexander Shulgin (1980). Pharmacology Notes II (The Shulgin Lab Books) (PDF). Lafayette, CA: Erowid. p. 293.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. ISSN 0341-1095.
- "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
- "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579.
- "Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF) (in Swedish) (published February 15, 2005). February 3, 2005. SFS 2005:26.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020.
- "Chapter 893: Drug Abuse Prevention and Control". The 2019 Florida Statutes. The Florida Legislature. Retrieved August 21, 2020.